Blog: Nestle receives green light on Pfizer deal
Michelle Russell | 6 November 2012
Swiss food group Nestle today (6 November) received approval from the Chinese Ministry of Commerce for its US$11.85bn deal to acquire Pfizer's infant nutrition business.
The approval brings Nestle another step closer to completing the acquisition, which was announced in April this year, enabling the world's largest infant nutrition group to extend its lead in this fast-growing category.
Pfizer Nutrition operates in more than 60 countries globally and 85% of sales are generated in emerging markets, meaning the acquisition effectively fills in the blanks on the map for Nestle. It will provide the company with increased scale in a high-growth, high-margin, category in fast-growing developing markets, CEO Paul Bulcke told investors as it emerged as victor of competitive auction process.
Nestle beat companies including Danone and Mead Johnson to seal the agreement. The next hurdle, however, is to receive approval from anti-trust bodies in several countries in order to fully complete the acquisition.
Synthetic biology group Intrexon Corp. hopes its acquisition of Okanagan Specialty Fruits (OSF) will help it tap into growing demand for fresh prepared fruits. ...
- Maspex: M&A opportunities in eastern Europe
- The just-food interview: Bega Cheese CEO
- Nestle's 2014 results: 10 Things to Learn
- Sustainability Watch: The US packaging challenge
- Why "simple" and "real" will be industry buzzwords
- Gruma FY earnings surge as margins improve
- UPDATE: Mondelez confirms Irish plant changes
- WhiteWave launches "Australian-style" yoghurt
- Bright Food "to buy 70% of Tnuva"
- 2 Sisters Food Group eyes Fox's job cuts